4D Molecular Therapeutics, Inc. (FDMT) financial statements and ratios from SEC XBRL: revenue $85.21M (TTM), net margin -164.4%, revenue growth 230194.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $85.21M |
| Net Margin | -164.4% |
| Revenue Growth (YoY) | 230194.6% |
| EPS Growth (YoY) | -18.8% |
| FCF Growth (YoY) | -20.8% |
| Price / Book | 2.18 |
| Price / Sales | 89.04 |
| FCF Yield | -31.2% |
| Altman Z-Score | 7.33 (safe) |
| Sector P/E (Healthcare) | 21.6 |
FDMT overview · FDMT earnings · FDMT KPIs · FDMT investor relations · FDMT ownership · FDMT peers · FDMT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.